Verrica Pharmaceuticals (VRCA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Verrica Pharmaceuticals (NASDAQ:VRCA) released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02), Fidelity Earnings reports.

Shares of Verrica Pharmaceuticals stock opened at $7.99 on Friday. The company has a market cap of $205.41 million and a PE ratio of -5.67. Verrica Pharmaceuticals has a twelve month low of $6.44 and a twelve month high of $23.29.

In other news, major shareholder Matt Davidson sold 20,558 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $11.72, for a total transaction of $240,939.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 190,850 shares of company stock worth $2,109,290 over the last quarter. Insiders own 40.20% of the company’s stock.

An institutional investor recently raised its position in Verrica Pharmaceuticals stock. Geode Capital Management LLC lifted its stake in shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) by 31.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,906 shares of the company’s stock after purchasing an additional 8,885 shares during the quarter. Geode Capital Management LLC owned about 0.14% of Verrica Pharmaceuticals worth $300,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 34.75% of the company’s stock.

Several analysts have issued reports on VRCA shares. HC Wainwright started coverage on Verrica Pharmaceuticals in a research note on Thursday, February 21st. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research cut Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 11th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Verrica Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $26.25.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Rockland Register and is owned by of Rockland Register. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://rocklandregister.com/2019/05/31/verrica-pharmaceuticals-vrca-posts-earnings-results-misses-estimates-by-0-02-eps.html.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Story: What is the Consumer Price Index (CPI)?

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.